

**STRIDES PHARMA ASIA PTE. LIMITED**  
**BALANCE SHEET AS AT 31 March 2025**

Amount in USD

	Particulars	Note No.	31-Mar-25	31-Mar-24
<b>I.</b>	<b>Equity and Liabilities</b>			
	<b>1. Shareholders' Funds</b>			
	(a) Share Capital	1	175,329,360	175,329,360
	(b) Reserves and Surplus	2	28,173,938	27,185,180
			<b>203,503,298</b>	<b>202,514,540</b>
	<b>2. Current liabilities</b>			
	(a) Trade payables	3	329,079	368,615
	(b) Other Current Liabilities	4	360	2,059,363
	(c) Short-term provisions	5	82,155	52,568
			<b>411,594</b>	<b>2,480,547</b>
	<b>TOTAL</b>		<b>203,914,892</b>	<b>204,995,087</b>
<b>II.</b>	<b>Assets</b>			
	<b>1. Non-Current Assets</b>			
	(a) Non- current investments	6	200,952,514	200,952,514
			<b>200,952,514</b>	<b>200,952,514</b>
	<b>2. Current assets</b>			
	(a) Cash and Cash Equivalents	7	119,807	130,868
	(b) Short-term Loans and Advances	8	2,842,570	3,911,705
			<b>2,962,377</b>	<b>4,042,573</b>
	<b>TOTAL</b>		<b>203,914,892</b>	<b>204,995,087</b>

**STRIDES PHARMA ASIA PTE. LIMITED**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2025**

Amount in USD

Particulars	Note No.	31-Mar-25	31-Mar-24
Other Income	9	60,970	6,585,578
<b>Total Revenue</b>		<b>60,970</b>	<b>6,585,578</b>
<b>Expenses</b>			
Other Expenses	10	58,581	137,725
Finance costs	11	2,557	2,770
<b>Total</b>		<b>61,138</b>	<b>140,496</b>
<b>Profit / (Loss) before exceptional items and taxes</b>		<b>(168)</b>	<b>2,248,926</b>
<b>Profit / (Loss) before taxes</b>		<b>(168)</b>	<b>2,248,926</b>
Tax Expense:			
(1) Current tax		2,719	-
<b>Profit / (Loss) for the year after tax</b>		<b>(2,887)</b>	<b>2,248,926</b>

**STRIDES PHARMA ASIA PTE. LIMITED**  
**Notes forming part of the financial statements**

**Note**

**No.**

<b>1 Share capital</b>		<b>Amount in USD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	<b>Issued, subscribed and fully paid-up</b>		
	Equity share capital	175,329,360	175,329,360
	<b>Total</b>	<b>175,329,360</b>	<b>175,329,360</b>

<b>2 Reserves and surplus</b>		<b>Amount in USD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	<b>1. Capital Reserve</b>	(1,122,154)	(1,122,154)
	<b>2. Surplus in Statement of Profit and Loss</b>		
	Opening Balance	28,304,978	25,602,204
	Add: Profit / (Loss) for the year	(2,887)	6,269,330
	Less: Equity dividend	994,000	(3,564,200)
	<b>Closing balance</b>	<b>28,173,938</b>	<b>27,185,180</b>
	<b>Total</b>	<b>28,173,938</b>	<b>27,185,180</b>

<b>3 Trade payables</b>		<b>Amount in USD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	Other than acceptances	329,079	368,615
	<b>Total</b>	<b>329,079</b>	<b>368,615</b>

<b>4 Other current liabilities</b>		<b>Amount in USD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	Dividend Payable	-	2,059,000
	- Statutory remittances	360	363
	<b>Total</b>	<b>360</b>	<b>2,059,363</b>

<b>5 Short-term provisions</b>		<b>Amount in USD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	<b>Provision - Others:</b>		
	- Provision for tax (net of advance tax)	82,154	52,568
	<b>Total</b>	<b>82,154</b>	<b>52,568</b>

<b>6 Non - current investments</b>		<b>Amount in USD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	Strides Pharma Global Pte Limited	196,481,042	196,481,042
	Trinity Pharma (Pty) Limited	4,471,472	4,471,472
	<b>Total</b>	<b>200,952,514</b>	<b>200,952,514</b>

<b>7 Cash and cash equivalents</b>		<b>Amount in USD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	Bank balance	119,807	130,868
	<b>Total</b>	<b>119,807</b>	<b>130,868</b>

Note  
No.

**8 Short-term loans and advances** **Amount in USD**

Particulars	31-Mar-25	31-Mar-23
<b>Unsecured, considered good</b>		
Receivable from related parties	2,815,704	3,911,705
- Advance tax	26,867	
<b>Total</b>	<b>2,842,570</b>	<b>3,911,705</b>

**9 Other Income** **Amount in USD**

Particulars	31-Mar-25	31-Mar-24
Profit/(Loss) on sale of investment	-	6,546,705
Guarantee Commission	19,868	11,237
Exchange fluctuation gain (net)	10,971	-
Interest Income	30,131	27,636
<b>Total</b>	<b>60,970</b>	<b>6,585,578</b>

**10 Other Expenses** **Amount in USD**

Particulars	31-Mar-25	31-Mar-24
Membership fees and subscription	1,745	246
Exchange fluctuation loss (net)	-	12,618
Legal & Professional fees	47,395	90,334
Rates and taxes	4,319	34,460
Payment to Auditors - For Statutory Audit	-	16,971
Provision for impairment of investment	(899)	150,678
Director sitting fees	6,021	6,000
Support service expenses- Arcolab	-	1,338
Others	-	497
<b>Total</b>	<b>58,581</b>	<b>313,142</b>

**11 Finance Cost** **Amount in USD**

Particulars	31-Mar-25	31-Mar-24
Bank Charges & Commission	2,557	3,105
<b>Total</b>	<b>2,557</b>	<b>3,105</b>